Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults

References

• Carter R, Mendis KN. Evolutionary and historical aspects of the burden of malaria. Clin Microbiol Rev 2002; 15:564 - 94; http://dx.doi.org/10.1128/CMR.15.4.564-594.2002; PMID: 12364370
   PubMed Web of Science ®Google Scholar
• Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005; 434:214 - 7; http://dx.doi.org/10.1038/nature03342; PMID: 15759000
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Facts on Malaria. 2013.
   Google Scholar
• Mandell GL, Douglas RG, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005.
   Google Scholar
• John CC, Moormann AM, Pregibon DC, Sumba PO, McHugh MM, Narum DL, Lanar DE, Schluchter MD, Kazura JW. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am J Trop Med Hyg 2005; 73:222 - 8; PMID: 16014863
   PubMed Web of Science ®Google Scholar
• John CC, Tande AJ, Moormann AM, Sumba PO, Lanar DE, Min XM, Kazura JW. Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J Infect Dis 2008; 197:519 - 26; http://dx.doi.org/10.1086/526787; PMID: 18275273
   PubMed Web of Science ®Google Scholar
• John CC, Zickafoose JS, Sumba PO, King CL, Kazura JW. Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein, and liver-stage antigen 1 vary by ages of subjects and by season in a highland area of Kenya. Infect Immun 2003; 71:4320 - 5; http://dx.doi.org/10.1128/IAI.71.8.4320-4325.2003; PMID: 12874308
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmüller B, et al, RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365:1863 - 75; http://dx.doi.org/10.1056/NEJMoa1102287; PMID: 22007715
   PubMed Web of Science ®Google Scholar
• Bejon P, Cook J, Bergmann-Leitner E, Olotu A, Lusingu J, Mwacharo J, Vekemans J, Njuguna P, Leach A, Lievens M, et al. Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J Infect Dis 2011; 204:9 - 18; http://dx.doi.org/10.1093/infdis/jir222; PMID: 21628653
   PubMed Web of Science ®Google Scholar
• Olotu A, Moris P, Mwacharo J, Vekemans J, Kimani D, Janssens M, Kai O, Jongert E, Lievens M, Leach A, et al. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria. PLoS One 2011; 6:e25786; http://dx.doi.org/10.1371/journal.pone.0025786; PMID: 21998698
   PubMed Web of Science ®Google Scholar
• Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, Lang T, Gould J, Dubois MC, Jongert E, et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis 2011; 11:102 - 9; http://dx.doi.org/10.1016/S1473-3099(10)70262-0; PMID: 21237715
   PubMed Web of Science ®Google Scholar
• Aide P, Dobaño C, Sacarlal J, Aponte JJ, Mandomando I, Guinovart C, Bassat Q, Renom M, Puyol L, Macete E, et al. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial. Vaccine 2011; 29:6059 - 67; http://dx.doi.org/10.1016/j.vaccine.2011.03.041; PMID: 21443960
   PubMed Web of Science ®Google Scholar
• Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, et al, RTS, S Malaria Vaccine Trial Team. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001; 358:1927 - 34; http://dx.doi.org/10.1016/S0140-6736(01)06957-4; PMID: 11747915
   PubMed Web of Science ®Google Scholar
• Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K, Glenn G, Ockenhouse CF, Garcon N, Schwenk R, et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 1998; 178:1139 - 44; http://dx.doi.org/10.1086/515657; PMID: 9806046
   PubMed Web of Science ®Google Scholar
• Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois MC, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359:2521 - 32; http://dx.doi.org/10.1056/NEJMoa0807381; PMID: 19064627
   PubMed Web of Science ®Google Scholar
• Ophorst OJ, Radosević K, Havenga MJ, Pau MG, Holterman L, Berkhout B, Goudsmit J, Tsuji M. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun 2006; 74:313 - 20; http://dx.doi.org/10.1128/IAI.74.1.313-320.2006; PMID: 16368986
   PubMed Web of Science ®Google Scholar
• Stewart VA, McGrath SM, Dubois PM, Pau MG, Mettens P, Shott J, Cobb M, Burge JR, Larson D, Ware LA, et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect Immun 2007; 75:2283 - 90; http://dx.doi.org/10.1128/IAI.01879-06; PMID: 17307942
   PubMed Web of Science ®Google Scholar
• Shott JP, McGrath SM, Pau MG, Custers JH, Ophorst O, Demoitié MA, Dubois MC, Komisar J, Cobb M, Kester KE, et al. Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice. Vaccine 2008; 26:2818 - 23; http://dx.doi.org/10.1016/j.vaccine.2008.03.080; PMID: 18455276
   PubMed Web of Science ®Google Scholar
• Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, Kostense S, Penders G, Helmus N, Koudstaal W, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77:8263 - 71; http://dx.doi.org/10.1128/JVI.77.15.8263-8271.2003; PMID: 12857895
   PubMed Web of Science ®Google Scholar
• Ophorst OJ, Kostense S, Goudsmit J, De Swart RL, Verhaagh S, Zakhartchouk A, Van Meijer M, Sprangers M, Van Amerongen G, Yüksel S, et al. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 2004; 22:3035 - 44; http://dx.doi.org/10.1016/j.vaccine.2004.02.011; PMID: 15297053
   PubMed Web of Science ®Google Scholar
• Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, Tomaras GD, De Rosa SC, McElrath MJ, NIAID HIV Vaccine Trials Network. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PLoS One 2010; 5:e13579; http://dx.doi.org/10.1371/journal.pone.0013579; PMID: 21048953
   PubMedGoogle Scholar
• Schuldt NJ, Aldhamen YA, Godbehere-Roosa S, Seregin SS, Kousa YA, Amalfitano A. Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice. Malar J 2012; 11:209; http://dx.doi.org/10.1186/1475-2875-11-209; PMID: 22720732
   PubMed Web of Science ®Google Scholar
• Schuldt NJ, Amalfitano A. Malaria vaccines: focus on adenovirus based vectors. Vaccine 2012; 30:5191 - 8; http://dx.doi.org/10.1016/j.vaccine.2012.05.048; PMID: 22683663
   PubMed Web of Science ®Google Scholar
• Rodrigues EG, Zavala F, Nussenzweig RS, Wilson JM, Tsuji M. Efficient induction of protective anti-malaria immunity by recombinant adenovirus. Vaccine 1998; 16:1812 - 7; http://dx.doi.org/10.1016/S0264-410X(98)00181-9; PMID: 9795385
   PubMed Web of Science ®Google Scholar
• Radosevic K, Rodriguez A, Lemckert AA, van der Meer M, Gillissen G, Warnar C, von Eyben R, Pau MG, Goudsmit J. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol 2010; 17:1687 - 94; http://dx.doi.org/10.1128/CVI.00311-10; PMID: 20826614
   PubMed Web of Science ®Google Scholar
• Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, Patterson N, Guerrero M, Bennett JW, McGrath S, et al. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 2013; 8:e55571; http://dx.doi.org/10.1371/journal.pone.0055571; PMID: 23457473
   PubMed Web of Science ®Google Scholar
• Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, Spring M, Mendoza-Silveiras J, McGrath S, Maiolatesi S, Reyes S, et al. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One 2011; 6:e25868; http://dx.doi.org/10.1371/journal.pone.0025868; PMID: 22003411
   PubMed Web of Science ®Google Scholar
• Sedegah M, Tamminga C, McGrath S, House B, Ganeshan H, Lejano J, Abot E, Banania GJ, Sayo R, Farooq F, et al. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One 2011; 6:e24586; http://dx.doi.org/10.1371/journal.pone.0024586; PMID: 22003383
   PubMed Web of Science ®Google Scholar
• Rodrigues EG, Claassen J, Lee S, Wilson JM, Nussenzweig RS, Tsuji M. Interferon-gamma-independent CD8+ T cell-mediated protective anti-malaria immunity elicited by recombinant adenovirus. Parasite Immunol 2000; 22:157 - 60; http://dx.doi.org/10.1046/j.1365-3024.2000.00289.x; PMID: 10672197
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmüller B, Issifou S, Kremsner PG, et al, RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367:2284 - 95; http://dx.doi.org/10.1056/NEJMoa1208394; PMID: 23136909
   PubMed Web of Science ®Google Scholar
• Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, Kostense S, Penders G, Helmus N, Koudstaal W, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77:8263 - 71; http://dx.doi.org/10.1128/JVI.77.15.8263-8271.2003; PMID: 12857895
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al, Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881 - 93; http://dx.doi.org/10.1016/S0140-6736(08)61591-3; PMID: 19012954
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, et al, VRC 205 Study Team. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010; 29:304 - 13; http://dx.doi.org/10.1016/j.vaccine.2010.10.037; PMID: 21034824
   PubMed Web of Science ®Google Scholar
• Radosevic K, Rodriguez A, Lemckert AA, van der Meer M, Gillissen G, Warnar C, von Eyben R, Pau MG, Goudsmit J. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol 2010; 17:1687 - 94; http://dx.doi.org/10.1128/CVI.00311-10; PMID: 20826614
   PubMed Web of Science ®Google Scholar
• Maizel JV Jr., White DO, Scharff MD. The polypeptides of adenovirus. II. Soluble proteins, cores, top components and the structure of the virion. Virology 1968; 36:126 - 36; http://dx.doi.org/10.1016/0042-6822(68)90122-0; PMID: 5669983
   PubMed Web of Science ®Google Scholar
• McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, et al, Step Study Protocol Team. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894 - 905; http://dx.doi.org/10.1016/S0140-6736(08)61592-5; PMID: 19012957
   PubMed Web of Science ®Google Scholar
• Kostense S, Mommaas B, Hendriks J, Verhoeven M, Ter Haak M, Tirion F, Wiesken E, Pau MG, Radosevic K, Goudsmit J. A peptide-based Plasmodium falciparum circumsporozoite assay to test for serum antibody responses to pre-erythrocyte malaria vaccines. Clin Vaccine Immunol 2011; 18:776 - 82; http://dx.doi.org/10.1128/CVI.00547-10; PMID: 21411600
   PubMed Web of Science ®Google Scholar
• Rock MT, Yoder SM, Talbot TR, Edwards KM, Crowe JE Jr.. Cellular immune responses to diluted and undiluted aventis pasteur smallpox vaccine. J Infect Dis 2006; 194:435 - 43; http://dx.doi.org/10.1086/505506; PMID: 16845626
   PubMed Web of Science ®Google Scholar
• Rock MT, Yoder SM, Wright PF, Talbot TR, Edwards KM, Crowe JE Jr.. Differential regulation of granzyme and perforin in effector and memory T cells following smallpox immunization. J Immunol 2005; 174:3757 - 64; PMID: 15749916
   PubMed Web of Science ®Google Scholar
• Rutigliano JA, Rock MT, Johnson AK, Crowe JE Jr., Graham BS. Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus. Virology 2005; 337:335 - 43; http://dx.doi.org/10.1016/j.virol.2005.04.032; PMID: 15916793
   PubMed Web of Science ®Google Scholar
• Rock MT, Crowe JE Jr.. Identification of a novel human leucocyte antigen-A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein. Immunology 2003; 108:474 - 80; http://dx.doi.org/10.1046/j.1365-2567.2003.01619.x; PMID: 12667209
   PubMed Web of Science ®Google Scholar